Target intelligence / Profile preview

Short-chain three-finger alpha-neurotoxin (Sc3FTx)

Target
Sc3FTx
Molecular classification
Three-finger toxin (3FTx) superfamily, Alpha-neurotoxin family, Polypeptide
01

Overview

Short-chain three-finger alpha-neurotoxins (Sc3FTxs) are a major class of toxic polypeptides found in the venom of elapid snakes, such as cobras, kraits, and sea snakes. These toxins are characterized by a conserved structural motif consisting of three beta-stranded loops extending from a central hydrophobic core, stabilized by four conserved disulfide bonds. Their primary biological function is the high-affinity, competitive antagonism of muscle-type nicotinic acetylcholine receptors (nAChR) at the postsynaptic membrane of the neuromuscular junction. By binding to the orthosteric site of the receptor, Sc3FTxs block the action of the neurotransmitter acetylcholine, leading to a failure of neuromuscular transmission. This results in rapid flaccid paralysis of skeletal muscles, which can progress to fatal respiratory failure if not treated promptly. In clinical practice, these toxins are the primary targets for neutralization by polyclonal antivenoms, although their small molecular size and low immunogenicity present significant therapeutic challenges. Ongoing research aims to develop more effective treatments, including broadly neutralizing monoclonal antibodies and synthetic inhibitors, to improve outcomes for snakebite victims.

Other names
Type I alpha-neurotoxinShort-chain neurotoxinShort-chain 3FTxPostsynaptic neurotoxinSαNTX
02

Mechanism of action

Neutralization of the toxin through steric hindrance or competitive binding, preventing the toxin from interacting with its physiological target (nAChR).

03

Biological functions

Nicotinic acetylcholine receptor antagonismNeuromuscular blockadeInhibition of synaptic transmission
04

Disease associations

Snakebite envenomationNeuromuscular paralysisRespiratory failure
05

Safety considerations

Rapid onset of paralysisHigh binding affinity making reversal difficultRisk of anaphylaxis from antivenomNarrow therapeutic window
06

Interacting drugs

Polyvalent antivenom

1 more in the full profile.

07

Biomarkers

Serum venom antigen levelsPtosisRespiratory rateElectromyography (decremental response)

Beyond the preview

Go deeper on Short-chain three-finger alpha-neurotoxin (Sc3FTx).

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Drug pipeline

Full profile access

Explore the programs pursuing this target and their development progress.

  • Drug candidates
  • Developers
  • Development stage

Clinical trials

Full profile access

Follow the clinical studies evaluating therapies directed at this target.

  • Trial design
  • Status
  • Readouts

Competitive landscape

Full profile access

Compare approaches across drug candidates, modalities, and indications.

  • Programs
  • Modalities
  • Indications

Literature & evidence

Full profile access

Investigate the research and source evidence behind target biology and development.

  • Publications
  • Sources
  • Analysis

Patents

Full profile access

Explore patent activity around therapies and technologies addressing this target.

  • Patents
  • Assignees
  • Technologies

Research & analysis

Full profile access

Connect target biology, drug development, and emerging evidence in your research.

  • Biology
  • Development news
  • Analysis

Bring the full picture into focus.

See how Gosset can support your research on Short-chain three-finger alpha-neurotoxin (Sc3FTx).

Explore the full profile

Gosset Free

Get started with Gosset.

Enter your work email and we’ll be in touch with next steps.

Work email preferred.

Book a call